Phenytoin is primarily utilized as an antiepileptic agent and belongs to the class IB antiarrhythmic drugs. It stabilizes cellular membranes by inhibiting the influx of fast sodium ions.

On October 27, 2017, the International Agency for Research on Cancer (IARC) of the World Health Organization (WHO) published its updated list of carcinogens, classifying phenytoin within Group 2B ("possibly carcinogenic to humans").

AccuSift provides high-performance competitive antibody pairs for phenytoin detection. These reagents offer exceptional inter-batch consistency and are optimized specifically for IVD kit development, including lateral flow assays, chemiluminescence, ELISA, and POCT platforms. Featuring high affinity and high specificity, they enable rapid and reliable detection.

Sensitivity: ELISA LOD: 0.1 μg/mL